Last synced on 23 May 2025 at 11:06 pm

System, Cystic Fibrosis Transmembrane Conductance Regulator Gene, Variant Gene Sequence Detection

Page Type
Product Code
Definition
The CFTR gene variant detection system is used to sequence specified regions of the CFTR gene to detect gene variants. It is intended as an aid in confirmatory diagnostic testing of individuals with suspected cystic fibrosis (CF), those with atypical or non-classic presentation of CF, or when other mutation panels have failed to identify both causative mutations. It is not intended for screening (carrier, newborn, population, or pre-implantation), prenatal diagnostic, or used for stand-alone diagnostic purposes
Physical State
Multiplex qualitative amplification with DNA sequencing detection methods. Should not include devices using non-sequencing based detection methods.
Technical Method
Uses multiplex polymerase chain reaction to amplify and sequence specific regions of the CFTR gene with DNA sequencing based detection method. Variants are identified by comparison to a specified reference sequence.
Target Area
Human peripheral whole blood or clinical samples
Regulation Medical Specialty
Immunology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.5900
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 866.5900 Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection system

§ 866.5900 Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection system.

(a) Identification. The CFTR gene mutation detection system is a device used to simultaneously detect and identify a panel of mutations and variants in the CFTR gene. It is intended as an aid in confirmatory diagnostic testing of individuals with suspected cystic fibrosis (CF), carrier identification, and newborn screening. This device is not intended for stand-alone diagnostic purposes, prenatal diagnostic, pre-implantation, or population screening.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: CFTR Gene Mutation Detection System.” See § 866.1(e) for the availability of this guidance document.

[70 FR 61738, Oct. 26, 2005]

System, Cystic Fibrosis Transmembrane Conductance Regulator Gene, Variant Gene Sequence Detection

Page Type
Product Code
Definition
The CFTR gene variant detection system is used to sequence specified regions of the CFTR gene to detect gene variants. It is intended as an aid in confirmatory diagnostic testing of individuals with suspected cystic fibrosis (CF), those with atypical or non-classic presentation of CF, or when other mutation panels have failed to identify both causative mutations. It is not intended for screening (carrier, newborn, population, or pre-implantation), prenatal diagnostic, or used for stand-alone diagnostic purposes
Physical State
Multiplex qualitative amplification with DNA sequencing detection methods. Should not include devices using non-sequencing based detection methods.
Technical Method
Uses multiplex polymerase chain reaction to amplify and sequence specific regions of the CFTR gene with DNA sequencing based detection method. Variants are identified by comparison to a specified reference sequence.
Target Area
Human peripheral whole blood or clinical samples
Regulation Medical Specialty
Immunology
Review Panel
Pathology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
866.5900
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 866.5900 Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection system

§ 866.5900 Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection system.

(a) Identification. The CFTR gene mutation detection system is a device used to simultaneously detect and identify a panel of mutations and variants in the CFTR gene. It is intended as an aid in confirmatory diagnostic testing of individuals with suspected cystic fibrosis (CF), carrier identification, and newborn screening. This device is not intended for stand-alone diagnostic purposes, prenatal diagnostic, pre-implantation, or population screening.

(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: CFTR Gene Mutation Detection System.” See § 866.1(e) for the availability of this guidance document.

[70 FR 61738, Oct. 26, 2005]